Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.
Former Teva CEO Levin returns to biopharma as chairman of upstart Ovid Therapeutics |
||||||||||||||||||
Jeremy Levin, known for his transformational efforts at Bristol-Myers Squibb ($BMY) and leadership stint at Teva Pharmaceuticals ($TEVA), has surfaced in the biotech world as chairman at Ovid Therapeutics, a startup working on rare neurological diseases with no treatments. There was no official release and Ovid doesn't have a website yet, but according to media reports, the company is privately held and based in New York; it's been able to raise about $5 million from undisclosed investors. "We're not here as a flash in the pan; Ovid is here to be a sustainable, long term company built in the area of orphan diseases of the brain," Levin said. He added that the company is "going phenomenally well, and it's meeting all of its goals." Levin was Novartis' ($NVS) head dealmaker from 2002 to 2007; VP of strategy and alliances at BMS from 2007 to 2012 and, following that, Teva CEO for less than two years. More
|